[go: up one dir, main page]

HUE054819T2 - Eljárások FXR agonista alkalmazására - Google Patents

Eljárások FXR agonista alkalmazására

Info

Publication number
HUE054819T2
HUE054819T2 HUE17709189A HUE17709189A HUE054819T2 HU E054819 T2 HUE054819 T2 HU E054819T2 HU E17709189 A HUE17709189 A HU E17709189A HU E17709189 A HUE17709189 A HU E17709189A HU E054819 T2 HUE054819 T2 HU E054819T2
Authority
HU
Hungary
Prior art keywords
methods
fxr agonists
fxr
agonists
Prior art date
Application number
HUE17709189A
Other languages
English (en)
Inventor
Bryan Laffitte
Michael Badman
Jin CHEN
Sam Lindgren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE054819T2 publication Critical patent/HUE054819T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HUE17709189A 2016-02-22 2017-02-20 Eljárások FXR agonista alkalmazására HUE054819T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298121P 2016-02-22 2016-02-22
US201662420661P 2016-12-12 2016-12-12

Publications (1)

Publication Number Publication Date
HUE054819T2 true HUE054819T2 (hu) 2021-10-28

Family

ID=58231666

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17709189A HUE054819T2 (hu) 2016-02-22 2017-02-20 Eljárások FXR agonista alkalmazására

Country Status (25)

Country Link
US (2) US11344540B2 (hu)
EP (2) EP3848031A1 (hu)
JP (1) JP6986022B2 (hu)
KR (1) KR20180115270A (hu)
CN (2) CN113679718A (hu)
AU (1) AU2017223155B2 (hu)
BR (1) BR112018016310A2 (hu)
CA (1) CA3013186A1 (hu)
CL (1) CL2018002359A1 (hu)
CY (1) CY1124300T1 (hu)
DK (1) DK3419625T3 (hu)
ES (1) ES2878575T3 (hu)
HK (1) HK1257647A1 (hu)
HR (1) HRP20211032T1 (hu)
HU (1) HUE054819T2 (hu)
IL (1) IL260784B (hu)
LT (1) LT3419625T (hu)
MX (1) MX2018010100A (hu)
PH (1) PH12018501656A1 (hu)
PL (1) PL3419625T3 (hu)
PT (1) PT3419625T (hu)
RU (1) RU2743075C2 (hu)
SI (1) SI3419625T1 (hu)
TW (1) TWI735546B (hu)
WO (1) WO2017145041A1 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100593T1 (it) 2015-03-31 2021-11-12 Enanta Pharm Inc Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso
KR20180115700A (ko) 2016-02-22 2018-10-23 노파르티스 아게 Fxr 효능제를 사용하는 방법
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
GB201616670D0 (en) * 2016-09-30 2016-11-16 Innospec Ltd Methods, compositions and uses relating thereto
CA3039124A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
AR114930A1 (es) 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
WO2019089670A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
US10730863B2 (en) 2017-11-01 2020-08-04 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid X receptor modulators
EP3704112B1 (en) 2017-11-01 2023-09-27 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid x receptor modulators
CA3081424A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
MX2020005557A (es) * 2017-11-30 2020-08-20 Novartis Ag Agonistas de fxr para el tratamiento de enfermedades hepaticas.
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
EA202192244A1 (ru) 2019-02-15 2022-01-24 Бристол-Маерс Сквибб Компани Замещенные амидные соединения, применимые в качестве модуляторов фарнезоидного x-рецептора
EP3924337A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US20220227804A1 (en) * 2019-05-29 2022-07-21 Qing Bile Therapeutics Inc. Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202122078A (zh) * 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
WO2021064575A1 (en) * 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
EP4329761A1 (en) 2021-04-28 2024-03-06 ENYO Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
HUE039155T2 (hu) 2013-11-05 2018-12-28 Novartis Ag Készítmények és eljárások farnezoid X receptorok modulálására
RU2700582C2 (ru) 2014-02-20 2019-09-18 Мерк Патент Гмбх Схема применения соединения fgf-18
KR20180115700A (ko) 2016-02-22 2018-10-23 노파르티스 아게 Fxr 효능제를 사용하는 방법
US11229634B2 (en) 2016-02-22 2022-01-25 Novartis Ag Methods for treating gastrointestinal disorders using FXR agonists

Also Published As

Publication number Publication date
CN108697702A (zh) 2018-10-23
CN113679718A (zh) 2021-11-23
HRP20211032T1 (hr) 2021-10-01
DK3419625T3 (da) 2021-07-12
ES2878575T3 (es) 2021-11-19
CA3013186A1 (en) 2017-08-31
CL2018002359A1 (es) 2018-12-07
SI3419625T1 (sl) 2021-08-31
PL3419625T3 (pl) 2021-10-25
US11344540B2 (en) 2022-05-31
EP3419625B1 (en) 2021-04-07
AU2017223155B2 (en) 2019-08-22
US20220313677A1 (en) 2022-10-06
RU2018133298A3 (hu) 2020-05-27
EP3848031A1 (en) 2021-07-14
RU2018133298A (ru) 2020-03-24
PH12018501656A1 (en) 2019-06-03
JP6986022B2 (ja) 2021-12-22
LT3419625T (lt) 2021-07-26
MX2018010100A (es) 2018-11-09
HK1257647A1 (zh) 2019-10-25
RU2743075C2 (ru) 2021-02-15
US20190046519A1 (en) 2019-02-14
JP2019511478A (ja) 2019-04-25
WO2017145041A1 (en) 2017-08-31
TWI735546B (zh) 2021-08-11
BR112018016310A2 (pt) 2018-12-26
CY1124300T1 (el) 2022-07-22
KR20180115270A (ko) 2018-10-22
AU2017223155A1 (en) 2018-08-09
IL260784B (en) 2022-04-01
PT3419625T (pt) 2021-07-07
EP3419625A1 (en) 2019-01-02
TW201735924A (zh) 2017-10-16

Similar Documents

Publication Publication Date Title
HK1257647A1 (zh) 使用fxr促效劑之方法
HK1257649A1 (zh) 使用fxr激動劑的方法
HK1257648A1 (zh) Fxr促效劑之使用方法
ZA201805680B (en) Methods for making l-glufosinate
EP3116878A4 (en) Fxr agonists and methods for making and using
SG11201702568QA (en) Holder for objects
HUE045962T2 (hu) Magmintatartó
GB201402343D0 (en) Method for identifying anomalies
IL246889A0 (en) A method for measuring engagement
SG11201607851PA (en) Method for analyzing mixture components
IL240359A0 (en) Rigid sliding unit manufacturing method
GB2528376B (en) Lubricant test method
IL265139B (en) Dopamine-b-hydroxylase inhibitors
IL264628A (en) Combination of fxr agonists
GB201612860D0 (en) Inhibitors
HUE053440T2 (hu) Embrió-mintavételezõ eljárás
GB201400960D0 (en) Sliding Sleeve Tool
HK1224016A1 (zh) 用於測定流體樣本的擴散
GB2524130B (en) Analysing Apparatus
DK3189327T3 (en) Ph-sensor for metaloxid
GB201700439D0 (en) Methods for assessing vaginal atrophy
EP3234547B8 (en) Dual component density sampler apparatus
PL3026555T3 (pl) Sposób zarządzania architekturą i powiązana architektura
GB201400386D0 (en) Agonists
TWI563269B (en) Apparatus for testing